Breast Cancer Research Program

乳腺癌研究计划

• 批准号: 10089817
• 负责人: LISA A CAREY
• 金额: $ 4.68万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10089817
• 关键词: Address; Adherence; African American; Animal Model; Autopsy; Award; Basic Science; Bioinformatics; Biological; Biological Markers; Biology; Breast; Cancer Center Support Grant; Cancer Research Project; Catchment Area; Cells; Cellular Structures; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Collaborations; Communities; Community Outreach; Country; County; DNA; DNA analysis; DNA sequencing; Data; Direct Costs; Discipline; Disease; ERBB2 gene; Elderly; Epidemiologist; Etiology; Exposure to; Extramural Activities; Faculty; Fostering; Funding; Gene Expression; Genetic; Genome Stability; Genomics; Goals; Grant; Growth; Health Sciences; Health Services; Health Services Accessibility; Health Services Research; Immune; Immunocompetent; Immunotherapeutic agent; Immunotherapy; Incidence; Infrastructure; Institution; Interdisciplinary Study; International; Intervention Trial; Investments; Leadership; Malignant Neoplasms; Metastatic breast cancer; Metastatic to; Minority-Serving Institution; Molecular Analysis; Multicenter Trials; Mus; Neoplasm Metastasis; Neoplasm Transplantation; North Carolina; Oncogene Activation; Oncology; Organ; Outcome; Patients; Peer Review; Plant Roots; Population Research; Population Study; Positioning Attribute; Primary Neoplasm; Proteomics; Public Health; Public Hospitals; Publishing; RNA; Regimen; Research; Research Design; Research Personnel; Research Support; Resources; Role; Science; Scientist; Seminal; Source; State Hospitals; Technology; Therapeutic; Tissues; Training; Translational Research; Tumor Subtype; Woman; Work; anticancer research; base; behavioral outcome; bench to bedside; cancer health disparity; cancer subtypes; cancer therapy; care outcomes; clinical care; clinical database; cohort; community engagement; design; epidemiology study; experience; genetic analysis; genetic manipulation; graduate student; hormone receptor-positive; human tissue; improved outcome; innovation; interest; intervention program; large datasets; malignant breast neoplasm; meetings; member; minority disparity; mouse model; new technology; novel; outreach; population based; predicting response; programs; prospective; racial disparity; recruit; response; senior faculty; single cell analysis; success; therapy adherence; tool; transcriptome sequencing; transcriptomics; transplant model; treatment optimization; treatment trial; triple-negative invasive breast carcinoma; tumor; tumor microenvironment; tumor-immune system interactions; undergraduate student

ABSTRACT: BREAST CANCER PROGRAM The Breast Cancer Program (BC) was an outgrowth of the basic, translational, population and clinical research of the LCCC Breast Cancer SPORE, which has been continuously funded since 1992. LCCC investment in faculty and infrastructure supports one of the country’s premier clinical and research breast programs, performing important interdisciplinary research in the past decade with members rising to national leadership positions. This knitting together of clinical, basic, and epidemiologic research is the hallmark of the Breast Program, and is reflected in the investment in faculty and resources fostered by including, in the last 5 years, over $10M in genomics/sequencing resources used for institutional as well as large multicenter trials. This commitment is reflected in patient-facing institutional trials examining clinical implications of breast cancer subtypes as well as LCCC leadership of collaborative tissue-based studies through the Translational Breast Cancer Research Consortium (TBCRC) and AURORA-US Project (https://auroraus.org), a multicenter, multiplatform analysis of DNA, RNA, and other alterations in metastases compared with matched primary tumors. The longitudinal and exceptional investment in the Carolina Breast Cancer Studies (CBCS) represents the largest and most heavily annotated population-based study ever performed addressing racial disparities in breast cancer, behavior and outcome. CBCS has received an additional $5M investment in this cycle and is providing the community with an increased understanding of the full range of breast cancer research from genomics /genetics to health services. Program strategic goals include: 1) genomic and genetic analyses of metastatic and primary breast cancers, 2) bench-to-bedside approaches using murine models, 3) translational discovery and strategies based on human tissue-based correlative science, 4) clinical trials and population- based studies leveraging and applying UNC science and community input to address the root causes of disparities. BC members include clinicians, basic researchers, statisticians, bioinformaticians, epidemiologists, and health services scientists. BC has long-term interest in North Carolina’s minority disparities, following the program’s seminal discoveries of the high incidence of triple negative breast cancer (TNBC) in younger African Americans, the subsequent molecular analysis showing the disparity is even more striking, and the surprising finding that the largest racial disparity in survival is in women with hormone receptor-positive disease, for whom access to care and adherence to treatment are key. The BC Program consists of 21 members who are associated with 10 basic science and 5 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members published 494 cancer-related articles, of which 56% were inter-programmatic and 15% were intra-programmatic (57% collaborative). In 2019, our program members held grants totaling $8.1M (direct cost) in cancer-relevant extramural funding, including $4.0M (direct costs) from the NCI and $1.8M other peer-reviewed funding.

摘要：乳腺癌计划 乳腺癌计划 (BC) 是基础研究、转化研究、人群研究和临床研究的产物 LCCC 乳腺癌 SPORE，自 1992 年以来一直持续资助。LCCC 投资于 师资和基础设施支持该国最重要的临床和研究乳腺项目之一， 在过去十年中进行了重要的跨学科研究，成员晋升为国家领导层 这种临床、基础和流行病学研究的结合是乳腺研究的标志。 计划，并反映在过去 5 年对师资和资源的投资中，包括： 超过 1000 万美元的基因组学/测序资源用于机构以及大型多中心试验。 承诺体现在面向患者的研究乳腺癌临床影响的机构试验中 亚型以及 LCCC 通过转化乳腺在基于组织的协作研究中的领导地位 癌症研究联盟 (TBCRC) 和 AURORA-US 项目 (https://auroraus.org)，一个多中心、 与匹配的原发灶相比，对转移灶中的 DNA、RNA 和其他变化进行多平台分析 卡罗莱纳州乳腺癌研究 (CBCS) 的纵向和特殊投资代表了这一点。 有史以来规模最大、注释最多的基于人群的研究，旨在解决种族差异问题 乳腺癌、行为和结果。 CBCS 在本周期中获得了 500 万美元的额外投资，并且正在实施。 让社区更好地了解乳腺癌的全方位研究 基因组学/遗传学到健康服务的计划战略目标包括：1) 基因组和遗传分析。 转移性和原发性乳腺癌，2) 使用小鼠模型的从实验室到临床的方法，3) 转化 基于人体组织相关科学的发现和策略，4）临床试验和人群- 基于研究，利用和应用北卡罗来纳大学的科学和社区投入来解决问题的根本原因 BC 成员绝大多数包括基础研究人员、统计学家、生物信息学家、流行病学家、 BC 省和卫生服务科学家对北卡罗来纳州的少数民族差异有着长期的兴趣。 该计划对非洲年轻人三阴性乳腺癌 (TNBC) 高发病率的开创性发现 美国人，随后的分子分析显示这种差异更加惊人，令人惊讶 发现生存率最大的种族差异是患有激素受体阳性疾病的女性，因为 BC 计划由 21 名成员组成，他们是获得护理和坚持治疗的关键。 与北卡罗来纳大学教堂山分校及其附属机构的 10 个基础科学部门和 5 个临床部门相关。 在上一个资助期内，项目成员发表了 494 篇癌症相关文章，其中 56% 2019 年，我们的计划成员进行了跨计划，15% 进行了计划内合作（57% 进行了协作）。 与癌症相关的外部资金总额为 810 万美元（直接成本），其中包括 400 万美元（直接成本） 来自 NCI 和 180 万美元其他同行评审资金。